Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

PURPOSE: To determine the maximum-tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). PATIEN...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Garcia-Manero, Guillermo, Gore, Steven D., Cogle, Christopher, Ward, Renee, Shi, Tao, MacBeth, Kyle J., Laille, Eric, Giordano, Heidi, Sakoian, Sarah, Jabbour, Elias, Kantarjian, Hagop, Skikne, Barry
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2011
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3675699/
https://ncbi.nlm.nih.gov/pubmed/21576646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.34.4226
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars